RxDoctor Payments Data

Anna Lansdell

Optometrist · Saltillo, MSNPI 1003487463

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 37.9% of the total. Reporting peaked in 2022 at $1,240 and has fallen 56.3% since, to $541 in 2025.

$3,625in general payments, 2019–2025

Across 139 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$1K
  • Alcon$787
  • Johnson & Johnson Vision Care, Inc.$763
  • Sun Pharmaceutical Industries Inc.$222
  • Optos, Inc.$124
  • Oyster Point Pharma, Inc.$118
  • plus $236 from 7 others

What the payments were for

  • Food & beverage$3,50097%
  • Entertainment$1243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,625 in reported general payments places this provider in the 85th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$38,316
Medicare patients
238
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost21$5,182
Brimonidine Tartrate13$1,861
Tobramycin-DexamethasoneTobramycin/Dexamethasone34$1,468
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$172
Latanoprost18$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$62$5,18221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Saltillo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →